journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://www.readbyqxmd.com/read/28543980/multicenter-analysis-of-the-use-of-transjugular-intrahepatic-portosystemic-shunt-tips-for-management-of-mpn-associated-portal-hypertension
#1
Christopher R Reilly, Daria V Babushok, Karlyn Martin, Jerry L Spivak, Michael Streiff, Ranjeeta Bahirwani, Jeffrey Mondschein, Brady Stein, Alison Moliterno, Elizabeth O Hexner
BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are clonal stem cell disorders defined by proliferation of one or more myeloid lineages, and carry an increased risk of vascular events and progression to myelofibrosis and leukemia. Portal hypertension (pHTN) occurs in 7-18% of MPN patients via both thrombotic and nonthrombotic mechanisms and portends a poor prognosis. Transjugular intrahepatic portosystemic shunt (TIPS) has been used in the management of MPN-associated pHTN; however, data on long-term outcomes of TIPS in this setting is limited and the optimal management of medically refractory MPN-associated pHTN is not known...
May 24, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28543765/ibrutinib-therapy-for-lymphoplasmacytic-lymphoma
#2
LETTER
Margaret J Helber, Jeremiah E Moore, AnnaLynn M Williams, Philip J Meacham, Paul G Rothberg, Clive S Zent
No abstract text is available yet for this article.
May 24, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28543165/recognition-of-early-mortality-in-multiple-myeloma-by-a-prediction-matrix
#3
Howard Terebelo, Shankar Srinivasan, Mohit Narang, Rafat Abonour, Cristina Gasparetto, Kathleen Toomey, James W Hardin, Gail Larkins, Amani Kitali, Robert M Rifkin, Jatin J Shah
Early mortality (EM; death ≤ 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%-14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors, are useful to assess overall prognosis; however, they cannot predict EM...
May 24, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28543934/clinical-impact-of-pre-transplant-use-of-multiple-tyrosine-kinase-inhibitors-on-the-outcome-of-allo-hsct-for-cml
#4
Takeshi Kondo, Tokiko Nagamura-Inoue, Arinobu Tojo, Fumitaka Nagamura, Naoyuki Uchida, Hirohisa Nakamae, Takahiro Fukuda, Takehiko Mori, Shingo Yano, Mineo Kurokawa, Hironori Ueno, Heiwa Kanamori, Hisako Hashimoto, Makoto Onizuka, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta, Kazuteru Ohashi
Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with chronic myelogenous leukemia in the chronic phase (CML-CP), and outcomes of TKI treatment for patients with CML-CP have been excellent. Since multiple TKIs are currently available, second-line or third-line TKI therapy is considered for patients who are intolerant of or resistant to the previous TKI treatment. Therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered only for patients with disease progression or for patients after treatment failure with multiple TKIs...
May 20, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28543380/chimeric-antigen-receptor-modified-t-cells-that-target-chemokine-receptor-ccr4-as-a-therapeutic-modality-for-t-cell-malignancies
#5
Liyanage P Perera, Meili Zhang, Masao Nakagawa, Michael N Petrus, Michiyuki Maeda, Marshall E Kadin, Thomas A Waldmann, Pin-Yu Perera
No abstract text is available yet for this article.
May 20, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28543356/pre-fibrotic-early-primary-myelofibrosis-vs-who-defined-essential-thrombocythemia-the-impact-of-minor-clinical-diagnostic-criteria-on-the-outcome-of-the-disease
#6
Georg Jeryczynski, Juergen Thiele, Bettina Gisslinger, Albert Wölfler, Martin Schalling, Andreas Gleiß, Sonja Burgstaller, Veronika Buxhofer-Ausch, Thamer Sliwa, Ernst Schlögl, Klaus Geissler, Maria-Theresa Krauth, Alexander Nader, Michael Vesely, Ingrid Simonitsch-Klupp, Leonhard Müllauer, Christine Beham-Schmid, Heinz Gisslinger
The 2016 revised WHO criteria for the diagnosis of pre-fibrotic/early primary myelofibrosis (pre-PMF) require at least one of the following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate dehydrogenase and splenomegaly. In this study, we evaluated the relative frequency of these four criteria in a group of 170 pre-PMF patients and compared them to 225 ET cases. More than 91% of pre-PMF cases showed one or more of these features required for diagnosis, by contrast with only 48...
May 20, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28516671/the-aggressive-peripheral-t-cell-lymphomas-2017
#7
James O Armitage
No abstract text is available yet for this article.
May 18, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28513000/a-hit-to-current-hit-wisdom-a-century-later-it-s-time-for-a-change
#8
Francesco Rodeghiero
No abstract text is available yet for this article.
May 16, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28512788/outcomes-of-patients-with-relapsed-refractory-hodgkin-lymphoma-progressing-after-autologous-stem-cell-transplant-in-the-current-era-of-novel-therapeutics-a-retrospective-analysis
#9
S M Bair, L Strelec, S J Nagle, S D Nasta, D J Landsburg, A R Mato, A W Loren, S J Schuster, E A Stadtmauer, J Svoboda
Patients with relapsed/refractory Hodgkin lymphoma (RR-HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents impacted prognosis in general population of patients with RR-HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR-HL with relapse post-ASCT...
May 16, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28512745/implementation-of-multi-disciplinary-care-reduces-maternal-mortality-in-women-with-sickle-cell-disease-living-in-low-resource-setting
#10
Eugenia Vicky Asare, Edeghonghon Olayemi, Theodore Boafor, Yvonne Dei-Adomakoh, Enoch Mensah, Harriet Ghansah, Yvonne Osei-Bonsu, Selina Crabbe, Latif Musah, Charles Hayfron-Benjamin, Brittany Covert, Adetola A Kassim, Andra James, Mark Rodeghier, Michael R DeBaun, Samuel A Oppong
Sickle cell disease (SCD) is associated with adverse pregnancy outcome. In women with SCD living in low-resource settings, pregnancy is associated with significantly increased maternal and perinatal mortality rates. We tested the hypothesis that implementing a multidisciplinary obstetric and hematology care team in a low-resource setting would significantly reduce maternal and perinatal mortality rates. We conducted a before-and-after study, at the Korle-Bu Teaching Hospital in Accra, Ghana, to evaluate the effect of a multidisciplinary obstetric-hematology care team for women with SCD in a combined SCD-Obstetric Clinic...
May 16, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28494520/characterization-of-tp53-mutations-in-clonal-cytopenia-of-undetermined-significance
#11
LETTER
Wei Wang, Mark J Routbort, Chi Young Ok, Keyur P Patel, Yi Sun, Rashmi Kanagal-Shamanna, L Jeffrey Medeiros, Sa A Wang
No abstract text is available yet for this article.
May 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28494518/correlates-of-resistance-and-relapse-during-blinatumomab-therapy-for-relapsed-refractory-acute-lymphoblastic-leukemia
#12
Ibrahim Aldoss, Joo Song, Tracey Stiller, Tina Nguyen, Joycelynne Palmer, Margaret O'Donnell, Anthony S Stein, Guido Marcucci, Stephen Forman, Vinod Pullarkat
We retrospectively analyzed 65 patients with refractory/relapsed (r/r) ALL who were treated with blinatumomab for predictors of leukemia response as well as clinical patterns of relapse and resistance with particular focus on downregulation of CD19 expression and extramedullary disease (EM-ALL). The complete remission (CR) rate was 51%, and 15 (45%) responders underwent allogeneic hematopoietic cell transplantation (HCT) in CR. High leukemia burden (bone marrow blasts >50%) (P=0.02), history of prior EM-ALL (P=0...
May 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28494514/urinary-prednisolone-excretion-is-a-determinant-of-serum-hepcidin-levels-in-renal-transplant-recipients
#13
LETTER
Michele F Eisenga, Robin P F Dullaart, Stefan P Berger, Daan J Touw, Stephan J L Bakker, Carlo A J M Gaillard
No abstract text is available yet for this article.
May 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28494509/estimates-of-total-body-iron-indicate-19-mg-and-38-mg-oral-iron-are-equivalent-for-the-mitigation-of-iron-deficiency-in-individuals-experiencing-repeated-phlebotomy
#14
Walter Bialkowski, Joseph E Kiss, David J Wright, Ritchard Cable, Rebecca Birch, Pam D'Andrea, Barbara J Bryant, Bryan R Spencer, Alan E Mast
Iron deficiency anemia is a common clinical condition often treated with tablets containing 65 mg of elemental iron. Such doses can elicit gastrointestinal side effects lowering patient compliance. Oral iron supplements also increase hepcidin production causing decreased fractional absorption of subsequent doses. Frequent blood donors often become iron deficient. Therefore, they were enrolled in a two-year study involving continued blood donations and randomization to receive no pill, placebo, 19, or 38 mg ferrous gluconate for 60 days...
May 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28494508/look-into-my-eyes-an-unusual-first-presentation-of-sickle-cell-disease
#15
Rupali Sood, Kim Jiramongkolchai, Michael Streiff, Christopher Gonzalez, Satish Shanbhag, Sophie Lanzkron, J Fernando Arevalo, Rakhi Naik
No abstract text is available yet for this article.
May 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28494506/minimal-residual-disease-eradication-with-epigenetic-therapy-in-core-binding-factor-acute-myeloid-leukemia
#16
Brittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, Farhad Ravandi, Jorge Cortes, Tapan Kadia, Betul Oran, Maro Ohanian, Alessandra Ferrajoli, Naveen Pemmaraju, Hagop M Kantarjian, Gautam Borthakur
Recurrent translocations, t(8;21) or inv(16), in core binding factor acute myeloid leukemia (CBF-AML) are amenable to monitoring for minimal residual disease (MRD) with reverse transcriptase polymerase chain reaction (RTPCR). Despite a favorable prognosis, disease relapse remains the single cause of treatment failure in CBF-AML. Fusion products of these translocations recruit epigenetic silencing complexes resulting in hematopoietic maturation arrest. We hypothesized that maintenance therapy with hypomethylating agents (HMA), including decitabine (DAC) and azacitidine (AZA) after induction/consolidation, can be used for MRD elimination to ultimately prolong relapse free survival...
May 11, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28474845/chronic-lymphocytic-leukemia-in-brazil-a-retrospective-analysis-of-1903-cases
#17
LETTER
Matheus Vescovi Gonçalves, Celso Arrais Rodrigues, Irene Gyongyver Heidemarie Lorand Metze, Marcelo Pitombeira Lacerda, Alita Azevedo, Cintia Machado, Carlos Sérgio Chiattone, Sérgio Fortier, Leila Perobelli, Maura Rosane Valerio Ikoma, Nelma Clementino, Nelson Hamerschlak, Inara Lucia Arce, Vivia Machado Stehl, Larissa Veloso Mendes Ommati, Danielle Leão Cordeiro Farias, Fernando Barroso Duarte, Valeria Buccheri, Ana Paula Azambuja, Denise Ramos Almeida, Vera Lucia Piratininga Figueiredo, Mihoko Yamamoto
No abstract text is available yet for this article.
May 5, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28474779/a-novel-in-vivo-model-for-studying-conditional-dual-loss-of-blimp-1-and-p53-in-b-cells-leading-to-tumor-transformation
#18
Antonio Sacco, Yawara Kawano, Michele Moschetta, Oksana Zavidij, Daisy Huynh, Michaela Reagan, Yuji Mishima, Salomon Manier, Jihye Park, Elizabeth Morgan, Satoshi Takagi, Kwok K Wong, Ruben Carrasco, Irene M Ghobrial, Aldo M Roccaro
The tumor suppressors B-Lymphocyte-Induced Maturation Protein-1 (BLIMP-1) and p53 play a crucial role in B-cell lymphomas, and their inactivation contributes to the pathogenesis of a wide spectrum of lymphoid malignancies, including diffuse large B-cell lymphomas (DLBCLs). Patients with activated B-cell-like (ABC) DLBCL may present with loss of BLIMP-1, c-Myc over-expression, decreased p53, and poor prognosis. Nevertheless, there is a lack of in vivo models recapitulating the biology of high-grade ABC DLBCL...
May 5, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28474745/daratumumab-monotherapy-compared-with-historical-control-data-in-heavily-pretreated-and-highly-refractory-patients-with-multiple-myeloma-an-adjusted-treatment-comparison
#19
Saad Z Usmani, Joris Diels, Tetsuro Ito, Maneesha Mehra, Imran Khan, Annette Lam
Daratumumab is a human CD38-directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD, and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone for patients with MM who have received ≥1 prior LOT. This study compared the efficacy of daratumumab monotherapy versus historical controls through adjusted treatment comparison...
May 5, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28474744/outcome-of-elderly-patients-after-failure-to-hypomethylating-agents-given-as-frontline-therapy-for-acute-myeloid-leukemia-aml-single-institution-experience
#20
Rama Nanah, Kristen McCullough, William Hogan, Kebede Begna, Mrinal Patnaik, Michelle Elliott, Mark Litzow, Aref Al-Kali
Outcomes of acute myeloid leukemia (AML) in elderly patients unfit for intensive chemotherapy is challenging. Hypomethylating agents (HMAs) can be effective in these patients but responses are usually short-lived. The majority of patients will either have stable disease or progress through therapy. We hereby describe the outcome of these patients at our institution after they fail HMAs. The data on 56 AML patients at Mayo Clinic, Rochester were reviewed. Patients were considered for our study if they received HMA as frontline therapy for their AML...
May 5, 2017: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"